EpiFOS Study – Jazz Pharmaceuticals – A Phase 1b multicenter, open-label study evaluating the safety and efficacy of Cannabidiol Oral Solution (CBD-OS) for the treatment of Focal-Onset Seizures.

A Phase 1b multicenter, open-label study evaluating the safety and efficacy of Cannabidiol Oral Solution (CBD-OS) for the treatment of Focal-Onset Seizures.

For more information, visit NCT07233239 on clinicaltrials.gov or please email clinicaltrialdisclosure@jazzpharma.com.